This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nichols, H. B. Articles by Newcomb, P. A. Search for Related Content PubMed PubMed Citation Articles by Nichols, H. B. Articles by Newcomb, P. A.

Oral Contraceptive Use and Risk of Breast Carcinoma In situ

¹ University of Wisconsin Paul P. Carbone Comprehensive Cancer Center and ² Department of Population Health Sciences, University of Wisconsin, Madison, Wisconsin; ³ H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; ⁴ Departments of Community & Family Medicine and Pediatrics, Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, New Hamsphire; and ⁵ Fred Hutchinson Cancer Research Center, Seattle, Washington

Requests for reprints: Amy Trentham-Dietz, Room 307, University of Wisconsin Comprehensive Cancer Center, WARF Building, 610 Walnut Street, Madison, WI 53726. Phone: 608-263-1946; Fax: 608-265-5330. E-mail: trentham{at}wisc.edu

There is some indication that oral contraceptive use may be associated with a small increase in risk of invasive breast cancer; however, oral contraceptive use in relation to breast carcinoma in situ (BCIS) has rarely been studied. We investigated oral contraceptive use in relation to risk of BCIS in a large population-based case-control study. Female residents of Wisconsin, Massachusetts, and New Hampshire aged 20 to 74 years with a new diagnosis of BCIS (n = 1,878) were identified from statewide tumor registries in 1997 to 2001. Age-matched female controls (n = 8,041) were randomly selected from population lists. Information on oral contraceptive use and other risk factors was collected during structured telephone interviews. Odds ratios (OR) and 95% confidence intervals (95% CI) were estimated using logistic regression. In multivariate models, ever use of oral contraceptives was associated with a small and marginally significant increase in BCIS overall (OR, 1.11; 95% CI, 0.99-1.25) and for ductal carcinoma in situ (OR, 1.15; 95% CI, 1.01-1.31). No strong associations were detected according to age started, duration, time since first or last use, or oral contraceptive use relative to the first full-term pregnancy. The slightly increased risk of BCIS seemed limited to former users (OR, 1.13; 95% CI, 1.00-1.27) and women without a family history of breast cancer (OR, 1.16; 95% CI, 1.01-1.32 for ever versus never use). Consistent with invasive breast cancer, these results suggest that oral contraceptive use is at most a minor contributor to BCIS risk. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2262–9)